Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -164.52% is in line with its 2-year average of -149.87%, around the middle of its 2-year range (-269.11%–-112.99%).
27.62% below its 12-month average of -128.92%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-07-31): -112.99%.
EBITDA MARGIN
-164.52%
EBITDA MARGIN AVG TTM
-128.92%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-27.62%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kestra Medical Technologies, Ltd.
Market Cap
$1.60B
EBITDA Margin
-164.52%
TTM Avg
-128.92%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.61B
EBITDA Margin
-512.70%
TTM Avg
-388.17%
3Y Avg
-265.21%
5Y Avg
-263.30%
Market Cap
$1.62B
EBITDA Margin
19.54%
TTM Avg
15.33%
3Y Avg
15.07%
5Y Avg
12.91%
Market Cap
$1.64B
EBITDA Margin
0.06%
TTM Avg
-4.29%
3Y Avg
-15.38%
5Y Avg
-22.40%
Market Cap
$1.62B
EBITDA Margin
-172.34%
TTM Avg
-3780.22%
3Y Avg
-1874.89%
5Y Avg
-1874.89%
Market Cap
$1.54B
EBITDA Margin
-158.44%
TTM Avg
-796.42%
3Y Avg
-796.42%
5Y Avg
-1562.06%
Market Cap
$1.53B
EBITDA Margin
-10.20%
TTM Avg
-140.78%
3Y Avg
-597.36%
5Y Avg
-597.36%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.60B | -164.52% | -128.92% | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.60B | 8.30% | 8.20% | 7.63% | 9.66% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -512.70% | -388.17% | -265.21% | -263.30% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 19.54% | 15.33% | 15.07% | 12.91% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 0.06% | -4.29% | -15.38% | -22.40% |
| Septerna Inc (SEPN)vs › | $1.62B | -172.34% | -3780.22% | -1874.89% | -1874.89% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 47.98% | 50.86% | 52.39% | 67.36% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -158.44% | -796.42% | -796.42% | -1562.06% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | -10.20% | -140.78% | -597.36% | -597.36% |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 33.84% | 32.51% | -30.03% | -1.40% |
Gross Margin
53.9%
EBITDA Margin
-164.5%
Operating Margin
-134.5%
Net Margin
-140.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-07-31 | -112.99% |
| 2026-04-30 | -129.27% |
| 2026-01-31 | -133.52% |
| 2025-10-31 | -130.21% |
| 2025-07-31 | -138.61% |
| 2025-04-30 | -269.11% |
| 2025-01-31 | -124.01% |
| 2024-10-31 | -117.37% |
| 2024-07-31 | -125.61% |
| 2024-04-30 | -167.57% |
| 2024-01-31 | -200.35% |
